CA2882771C — Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
Assigned to Novartis AG · Expires 2021-02-23 · 5y expired
What this patent protects
The present invention relates to the use of the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester in combination with the ARB valsartan for the manufacture of a medicament for the improvement, stabilization or…
USPTO Abstract
The present invention relates to the use of the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester in combination with the ARB valsartan for the manufacture of a medicament for the improvement, stabilization or delayed worsening in NYHA classification in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling such as heart failure with preserved ejection fraction. The present invention also relates to the use of the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester in combination with the ARB valsartan for the improvement, stabilization or delayed worsening in NYHA classification in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling such as heart failure with preserved ejection fraction.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.